Trials / Unknown
UnknownNCT04428073
Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
A Phase I Trial of a Therapeutic Vaccine (Covax-19™) in SARS-CoV-2 Infected Patients
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- GeneCure Biotechnologies · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
GC004 is a Phase I trial to evaluate the safety and the immune responses of a therapeutic vaccine in SARS-CoV-2 infected patients. Covid-19 confirmed patients with mild or no symptoms will be enrolled sequentially into low dose and high dose groups. Following the vaccination subjects who received at least one vaccination will be followed for safety through week 26.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Covax-19™ | Therapeutic vaccine for SARS-CoV-2 infection |
Timeline
- Start date
- 2020-07-01
- Primary completion
- 2021-07-01
- Completion
- 2021-12-01
- First posted
- 2020-06-11
- Last updated
- 2020-06-11
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04428073. Inclusion in this directory is not an endorsement.